BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nippon Kayaku readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nippon Kayaku's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06564324-2075@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT06564324)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Pos
 itive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients\n
 Estimated primary completion: January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/taletrectinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06564324
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154706-2075@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT07154706)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Po
 sitive NSCLC (TRUST-IV)\nEstimated primary completion: 30 August 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/taletrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07154706
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
